Seely Lynn 4
4 · Lyell Immunopharma, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Lyell (LYEL) CEO Seely Lynn Receives Awards, Sells 438 Shares
What Happened
Seely Lynn, President & CEO and director of Lyell Immunopharma (LYEL), received awards/derivative grants and had a small automatic sale to cover taxes. On Feb 9, 2026 Lynn was issued 20,000 shares (performance-based RSUs) at $0.00 per share after performance criteria were certified. On Feb 10, 2026 Lynn was granted a 155,000-share derivative award (reported at $0.00). Also on Feb 10, 2026 Lynn sold 438 shares in an open-market/private sale at $23.12 per share, generating proceeds of $10,127.
Key Details
- Transaction dates: Feb 9, 2026 (20,000 RSUs issued); Feb 10, 2026 (155,000 derivative grant; 438-share sale). Filing date: Feb 11, 2026 (covers Feb 9–10 transactions).
- Sale price/value: 438 shares @ $23.12 = $10,127 (disposed).
- Award values: 20,000 and 155,000 shares reported at $0.00 (awards/derivative grants).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes:
- F1: 20,000 performance-based RSUs were issued upon certification of performance criteria (granted Feb 9, 2024; issued Feb 9, 2026).
- F2: The 438 shares were automatically sold to cover tax withholding from the settlement of vested RSUs.
- F3: The 155,000-share derivative award is subject to a vesting schedule: 12.5% vests six months after Feb 9, 2026, then 1/48th monthly thereafter until fully vested (typical multi-year vesting).
- Filing timeliness: Filed Feb 11, 2026 for transactions on Feb 9–10; appears to be within the normal Form 4 reporting window.
Context
The sizable entries are awards/derivative grants (not open-market purchases) and are subject to vesting — they do not represent immediately marketable shares. The small sale was an automatic, routine tax-withholding sale tied to RSU settlement, not necessarily a discretionary sell signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-09+20,000→ 82,159 total - Sale
Common Stock
[F2]2026-02-10$23.12/sh−438$10,127→ 81,721 total - Award
Option (right to buy)
[F3]2026-02-10+155,000→ 155,000 totalExercise: $23.71Exp: 2036-02-09→ Common Stock (155,000 underlying)
Footnotes (3)
- [F1]Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.
- [F2]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F3]Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.